Peter Lawson
Stock Analyst at Barclays
(1.94)
# 3,158
Out of 5,124 analysts
99
Total ratings
40.23%
Success rate
-9.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Peter Lawson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals | Maintains: Overweight | $19 → $22 | $21.01 | +4.71% | 5 | Nov 4, 2025 | |
| INCY Incyte | Maintains: Overweight | $90 → $101 | $98.77 | +2.26% | 1 | Oct 29, 2025 | |
| ONC BeOne Medicines AG | Initiates: Overweight | $385 | $303.81 | +26.72% | 1 | Sep 18, 2025 | |
| IDYA IDEAYA Biosciences | Initiates: Overweight | $40 | $34.57 | +15.71% | 1 | Sep 4, 2025 | |
| SDGR Schrödinger | Initiates: Overweight | $25 | $17.88 | +39.82% | 1 | Aug 14, 2025 | |
| REPL Replimune Group | Downgrades: Equal-Weight | $17 → $3 | $9.72 | -69.14% | 4 | Jul 23, 2025 | |
| EXEL Exelixis | Maintains: Equal-Weight | $29 → $40 | $43.83 | -8.74% | 6 | Jul 10, 2025 | |
| MGNX MacroGenics | Maintains: Overweight | $8 → $3 | $1.61 | +86.34% | 9 | May 14, 2025 | |
| FATE Fate Therapeutics | Maintains: Overweight | $10 → $2 | $0.98 | +103.54% | 4 | May 14, 2025 | |
| KPTI Karyopharm Therapeutics | Maintains: Overweight | $5 → $10 | $7.36 | +35.87% | 3 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $2.73 | +46.52% | 7 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $22 → $6 | $15.31 | -60.81% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $11 | $10.39 | +5.87% | 1 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $16 | $11.86 | +34.91% | 8 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $15 | $7.05 | +112.77% | 2 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $14 | $23.83 | -41.25% | 7 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $3 | $1.24 | +141.94% | 5 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $3 | $1.00 | +200.00% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $4 | $1.32 | +203.03% | 1 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $60 | $79.65 | -24.67% | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $17 | $8.46 | +100.95% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $66 | $34.60 | +90.75% | 2 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $31 | $18.97 | +63.42% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $13 | $8.86 | +46.73% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $2.90 | +72.41% | 4 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3.5 | $4.26 | -17.84% | 4 | Jul 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $355 → $365 | $131.16 | +178.29% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $46 | $27.22 | +68.99% | 2 | Oct 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $450 | $42.28 | +964.33% | 1 | Mar 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $17 → $45 | $2.05 | +2,095.12% | 2 | Jan 23, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $16 → $45 | $52.44 | -14.19% | 2 | Jan 23, 2018 |
Syndax Pharmaceuticals
Nov 4, 2025
Maintains: Overweight
Price Target: $19 → $22
Current: $21.01
Upside: +4.71%
Incyte
Oct 29, 2025
Maintains: Overweight
Price Target: $90 → $101
Current: $98.77
Upside: +2.26%
BeOne Medicines AG
Sep 18, 2025
Initiates: Overweight
Price Target: $385
Current: $303.81
Upside: +26.72%
IDEAYA Biosciences
Sep 4, 2025
Initiates: Overweight
Price Target: $40
Current: $34.57
Upside: +15.71%
Schrödinger
Aug 14, 2025
Initiates: Overweight
Price Target: $25
Current: $17.88
Upside: +39.82%
Replimune Group
Jul 23, 2025
Downgrades: Equal-Weight
Price Target: $17 → $3
Current: $9.72
Upside: -69.14%
Exelixis
Jul 10, 2025
Maintains: Equal-Weight
Price Target: $29 → $40
Current: $43.83
Upside: -8.74%
MacroGenics
May 14, 2025
Maintains: Overweight
Price Target: $8 → $3
Current: $1.61
Upside: +86.34%
Fate Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $10 → $2
Current: $0.98
Upside: +103.54%
Karyopharm Therapeutics
May 13, 2025
Maintains: Overweight
Price Target: $5 → $10
Current: $7.36
Upside: +35.87%
May 12, 2025
Maintains: Overweight
Price Target: $5 → $4
Current: $2.73
Upside: +46.52%
May 8, 2025
Maintains: Underweight
Price Target: $22 → $6
Current: $15.31
Upside: -60.81%
May 2, 2025
Maintains: Overweight
Price Target: $32 → $11
Current: $10.39
Upside: +5.87%
May 2, 2025
Maintains: Overweight
Price Target: $32 → $16
Current: $11.86
Upside: +34.91%
May 1, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $7.05
Upside: +112.77%
Apr 23, 2025
Maintains: Overweight
Price Target: $29 → $14
Current: $23.83
Upside: -41.25%
Apr 2, 2025
Maintains: Equal-Weight
Price Target: $11 → $3
Current: $1.24
Upside: +141.94%
Mar 7, 2025
Maintains: Overweight
Price Target: $14 → $3
Current: $1.00
Upside: +200.00%
Feb 27, 2025
Maintains: Overweight
Price Target: $9 → $4
Current: $1.32
Upside: +203.03%
Sep 27, 2024
Maintains: Overweight
Price Target: $54 → $60
Current: $79.65
Upside: -24.67%
Sep 10, 2024
Maintains: Overweight
Price Target: $14 → $17
Current: $8.46
Upside: +100.95%
Aug 9, 2024
Maintains: Overweight
Price Target: $92 → $66
Current: $34.60
Upside: +90.75%
Jul 15, 2024
Maintains: Overweight
Price Target: $20 → $31
Current: $18.97
Upside: +63.42%
May 24, 2024
Maintains: Overweight
Price Target: $18 → $13
Current: $8.86
Upside: +46.73%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $2.90
Upside: +72.41%
Jul 7, 2022
Maintains: Overweight
Price Target: $7 → $3.5
Current: $4.26
Upside: -17.84%
Aug 6, 2021
Maintains: Underweight
Price Target: $355 → $365
Current: $131.16
Upside: +178.29%
Oct 22, 2020
Upgrades: Overweight
Price Target: $46
Current: $27.22
Upside: +68.99%
Mar 4, 2020
Initiates: Overweight
Price Target: $450
Current: $42.28
Upside: +964.33%
Jan 23, 2018
Upgrades: Buy
Price Target: $17 → $45
Current: $2.05
Upside: +2,095.12%
Jan 23, 2018
Upgrades: Buy
Price Target: $16 → $45
Current: $52.44
Upside: -14.19%